^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF G469A

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases. (PubMed, Virchows Arch)
    In conclusions, MSO shares histomolecular overlap with primary thyroid carcinoma, validating WHO 2022 thyroid tumor classification for risk stratification in struma ovarii. Conservative surgical management achieves excellent outcomes in low-grade cases.
    Journal • BRCA Biomarker
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • RET (Ret Proto-Oncogene) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • KMT2C (Lysine Methyltransferase 2C) • RAS (Rat Sarcoma Virus) • NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • KRT19 (Keratin 19) • PAX8 (Paired box 8) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    BRAF mutation • RET fusion • PTEN mutation • RET mutation • HRAS mutation • NRAS Q61 • BRAF G469A
    5ms
    Whole-Exome Sequencing Analysis of Inflammatory Bowel Disease-Associated Serrated Dysplasia. (PubMed, Int J Mol Sci)
    The SSL-like dysplasia exhibited distinct clinicopathologic and molecular characteristics compared with its sporadic counterpart. Similarly, serrated dysplasia NOS displayed unique molecular features compared with SSL-like dysplasia and could carry a higher risk of malignancy.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • MLH1 (MutL homolog 1) • KMT2C (Lysine Methyltransferase 2C) • MUTYH (MutY homolog) • EXT1 (Exostosin Glycosyltransferase 1)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • BRAF V600 • PTEN mutation • BRAF G469A
    9ms
    Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature. (PubMed, World J Clin Oncol)
    Due to the rarity of co-mutations, the case not only enriches the limited literature on NSCLC harbouring BRAF G469A and echinoderm microtubule associated protein like-4 mutations, but also suggests the efficacy and safety of specific multiple-drug therapy in such patients.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    BRAF mutation • ALK rearrangement • ALK mutation • BRAF G469A
    1year
    Early genetic divergence of high-grade carcinomas originating from low-grade ovarian serous neoplasms. (PubMed, Mod Pathol)
    In summary, synchronous and metachronous low-grade serous neoplasms and higher-grade carcinomas are clonally related. Early genetic divergence, most evident in cases with TP53 mutations, suggests that high-grade transformation may be a relatively early molecular event.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
    |
    TP53 mutation • KRAS G12D • TP53 wild-type • KRAS G12 • BRAF G469A
    over1year
    Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation. (PubMed, IJU Case Rep)
    Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. The disease has remained stable for more than 18 months. The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.
    Journal • PD(L)-1 Biomarker • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF G469A
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • cisplatin • gemcitabine
    over1year
    A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer. (PubMed, Cancer Med)
    Our large-scale analysis characterized the prevalence and mutational landscape of BRAF G469V/A-mutant NSCLC and proposed gefitinib as a potential option, providing a basis for further investigations on treating BRAF-mutated NSCLC.
    Retrospective data • Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
    |
    BRAF V600E • KRAS mutation • BRAF mutation • BRAF G469V • BRAF G469A
    |
    gefitinib
    over1year
    BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. (PubMed, Leuk Lymphoma)
    Although the acquisition of BRAF mutation during disease progression did not correlate with unfavorable outcomes, its clearance through chemotherapy or stem cell transplant exhibited favorable outcomes (median overall survival of 34.8 months versus 10.4 months, p = 0.047). Furthermore, G469A was the most frequently observed BRAF mutation, differing from solid tumors and hairy cell leukemia, where V600E mutations were predominant.
    Clinical data • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • RAS mutation • BRAF G469A
    over1year
    SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway. (PubMed, Anticancer Res)
    The SH003 and dabrafenib combination can be potentially developed as an effective treatment strategy for addressing lung cancer patients with the BRAF G469A mutation.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF G469A
    |
    Tafinlar (dabrafenib)
    almost2years
    Next-generation sequencing for pediatric CNS tumors: does it add value in a middle-income country setup? (PubMed, Front Oncol)
    Nine patients received targeted therapy; dabrafenib/trametinib (6), pembrolizumab (2), and entrectinib (1), mostly upon tumor progression (7). Outsourcing of NGS testing was feasible; however, criteria for case selection are needed. In addition, local capacity-building in conducting the test, interpretation of the results, and access to "new drugs" continue to be a challenge in LMICs.
    Journal • PD(L)-1 Biomarker • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase) • STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
    |
    BRAF mutation • BRAF K601E • BRAF G469A • BRAF K601
    |
    TruSight RNA Pan-Cancer Panel
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib)
    almost2years
    Genomic Landscape of NSCLC in the Republic of Ireland. (PubMed, JTO Clin Res Rep)
    Actionable alterations were identified in 53.4% of the patients, and KRAS was the most common oncogenic driver alteration. Our study revealed a lower prevalence of patients whose tumor harbors ALK, ROS1, and RET fusions, compared with similar data sets.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS G12C • BRAF mutation • HER-2 amplification • MET amplification • RET fusion • MET exon 14 mutation • ROS1 fusion • KRAS G12A • KRAS G12 • FGFR3 fusion • BRAF G469A • NTRK fusion
    2years
    Next generation sequencing for CNS tumors in children; does it add value in a Middle-Income Country setup? (SNO 2023)
    Eight patients received targeted therapy; Dabrafenib/Trametinib (5), Pembrolizumab (2), Entrectinib (1), while radio-chemotherapy was used in the others. Sent abroad NGS testing was feasible, however local capacity building is necessary. In this highly selected tumor cohort, high percentage of targetable alterations were identified. NGS was helpful to characterize tumors more and to offer alternative therapies.
    Clinical • PD(L)-1 Biomarker • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase) • STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
    |
    BRAF mutation • BRAF K601E • BRAF G469A • BRAF K601
    |
    TruSight RNA Pan-Cancer Panel
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib)
    2years
    Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. (PubMed, Histopathology)
    Our results highlight the clinical utility of molecular sequencing in SO, based on this limited number of cases. However, as malignant SO evolve slowly, more extensive molecular studies in SO with more than 10 years' follow-up are required to draw any conclusions on the prognostic value of the associated gene alterations.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF mutation • TERT mutation • BRAF G469A